View Post

Maintaining Full Doses of Chemotherapy Can Be Key for Breast Cancer Survival

In In The News by Barbara Jacoby

Source: PR Newswire From: finance.yahoo.com Study from Alberta, Canada, finds early dose reduction of adjuvant FEC-D chemotherapy negatively impacts overall survival rates for women with intermediate- or high-risk breast cancer Physicians should attempt to maintain full doses of chemotherapy, especially early in the treatment course, for intermediate or high risk breast cancer patients, according to new research published in the …

View Post

Breast Cancer Drug Available on CDF

In In The News by Barbara Jacoby

A potentially life-extending drug combination for some people with advanced breast cancer will be made available on England’s Cancer Drugs Fund (CDF) following a recommendation by the National Institute for Health and Care Excellence (NICE). The draft guidance recommended ribociclib (Kisqali, Novartis) with fulvestrant (Faslodex, AstraZenica) as an option for people with hormone receptor-positive, human epidermal growth factor receptor 2 …

View Post

CDK4/6 Inhibitors for Metastatic Breast Cancer: What You Need to Know

In Clinical Trials by Barbara Jacoby

By: BRIELLE BENYON From: oncnursingnews.com The advent of CDK4/6 inhibitors has caused landmark change in the treatment and outcomes of patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer. Three agents were already on the market – palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) – with a fourth, alpelisib (Piqray), approved this May. This could change the space even more …

View Post

CDK4/6 Inhibitors Firmly Established in HR+ Breast Cancer, OS Data Awaited

In Clinical Trials by Barbara Jacoby

By: Gina Columbus From: onclive.com The improvement in progression-free survival (PFS) that has been observed with CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer has led to changes in clinical practice. However, physicians are still awaiting further overall survival (OS) findings that will solidify the use of these agents, said Daphne B. Stewart, MD. Thus far, …

View Post

Continuous chemotherapy improves outcomes and quality of life in advanced breast cancer

In Clinical Trials by Barbara Jacoby

Source: European Society for Medical Oncology From: eurekalert.org Continuous chemotherapy shows greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented at the ESMO Breast Cancer Congress 2019, 2-4 May, Berlin, Germany. (1,2,3) The phase III study randomised 420 patients with …

View Post

Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour eFrom: onclive.com The collective results of the MINDACT and TAILORx trials provided a better directive in terms of whether or not to give endocrine therapy alone or in combination with chemotherapy for patients with node-negative, early-stage hormone receptor (HR)–positive, HER2-negative breast cancer, said Mariana Chavez Mac Gregor, MD, MSc. “In patients who have early-stage HR-positive, HER2-negative disease, …

View Post

CTC Counts Hold Value in Therapy Selection for Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Tony Hagen From: targetedonc.com At the 2018 San Antonio Breast Cancer Symposium, data demonstrated that use of circulating tumor-cell (CTC) counts had strong value for selecting endocrine therapy compared to chemotherapy in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. A CTC cutoff value was used to determine first-line treatment in this double-arm, randomized trial. There was high concordance between clinician’s choice …